All In Biotech

Drug Trial Radar · NCT00779103

Histrelin Subcutaneous Implant in Children With Central Precocious Puberty

Phase III, Open-Label Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Children With Central Precocious Puberty

Last checked: Nov 20, 2026Latest source record: Jan 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

36

Actual

Start

Sep 2004

Primary completion

Aug 2011

Study completion Apr 2012

Sponsor

Sponsor type
Industry
First posted
Oct 24, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 years, up to 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to follow and collect additional medical and developmental information on children after histrelin subcutaneous implant therapy is discontinued.

Conditions

  • Central Precocious Puberty

Interventions

  • Histrelin Subcutaneous ImplantDrug

    histrelin subcutaneous 50 mg implant

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Luteinizing Hormone (LH)Time frame: Baseline - 6 Months Post Last Implant

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.